Karyopharm Therapeutics Stock Analysis

KPTI Stock  USD 1.51  0.03  2.03%   
Karyopharm Therapeutics is undervalued with Real Value of 2.71 and Target Price of 6.67. The main objective of Karyopharm Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Karyopharm Therapeutics is worth, separate from its market price. There are two main types of Karyopharm Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Karyopharm Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Karyopharm Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Karyopharm Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Karyopharm Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Karyopharm Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Karyopharm Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Karyopharm Stock Analysis Notes

About 68.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.25. Karyopharm Therapeutics had not issued any dividends in recent years. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Karyopharm Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 442 people. To find out more about Karyopharm Therapeutics contact Richard MBA at 617 658 0600 or learn more at https://www.karyopharm.com.

Karyopharm Therapeutics Quarterly Total Revenue

33.75 Million

Karyopharm Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Karyopharm Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Karyopharm Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Karyopharm Therapeutics is way too risky over 90 days horizon
Karyopharm Therapeutics may become a speculative penny stock
Karyopharm Therapeutics appears to be risky and price may revert if volatility continues
Karyopharm Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 146.03 M. Net Loss for the year was (143.1 M) with profit before overhead, payroll, taxes, and interest of 151.86 M.
Karyopharm Therapeutics currently holds about 170.85 M in cash with (92.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Karyopharm Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 68.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Karyopharm Therapeutics Inc. Receives Average Rating of Moderate Buy from Analysts - Defense World

Karyopharm Therapeutics Upcoming and Recent Events

Earnings reports are used by Karyopharm Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Karyopharm Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Karyopharm Largest EPS Surprises

Earnings surprises can significantly impact Karyopharm Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-02-29
2023-12-31-0.31-0.36-0.0516 
2023-08-02
2023-06-30-0.34-0.290.0514 
2014-08-07
2014-06-30-0.49-0.55-0.0612 
View All Earnings Estimates

Karyopharm Therapeutics Thematic Classifications

In addition to having Karyopharm Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters Idea
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Karyopharm Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Karyopharm Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Karyopharm Therapeutics backward and forwards among themselves. Karyopharm Therapeutics' institutional investor refers to the entity that pools money to purchase Karyopharm Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Marshall Wace Asset Management Ltd2023-12-31
1.9 M
Bnp Paribas Arbitrage, Sa2023-12-31
1.8 M
Adage Capital Partners Gp Llc2023-12-31
1.7 M
Millennium Management Llc2023-12-31
1.5 M
Cam Group Holding A/s2023-12-31
1.5 M
Deutsche Bank Ag2023-12-31
1.3 M
Jpmorgan Chase & Co2023-12-31
1.2 M
Alphacentric Advisors, Llc2023-12-31
1.1 M
Tejara Capital Ltd2023-12-31
M
Blackrock Inc2023-12-31
10.1 M
Vanguard Group Inc2023-12-31
8.7 M
Note, although Karyopharm Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Karyopharm Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 173.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Karyopharm Therapeutics's market, we take the total number of its shares issued and multiply it by Karyopharm Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Karyopharm Profitablity

Karyopharm Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Karyopharm Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Karyopharm Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Karyopharm Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Karyopharm Therapeutics' profitability requires more research than a typical breakdown of Karyopharm Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.98) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.12) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.12.
Last ReportedProjected for 2024
Return On Capital Employed(0.76)(0.72)
Return On Assets(0.60)(0.62)
Return On Equity 1.05  1.10 

Management Efficiency

Karyopharm Therapeutics has return on total asset (ROA) of (0.2705) % which means that it has lost $0.2705 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9105) %, meaning that it created substantial loss on money invested by shareholders. Karyopharm Therapeutics' management efficiency ratios could be used to measure how well Karyopharm Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Karyopharm Therapeutics' current Return On Equity is estimated to increase to 1.10, while Return On Capital Employed is forecasted to increase to (0.72). As of now, Karyopharm Therapeutics' Other Current Assets are increasing as compared to previous years. The Karyopharm Therapeutics' current Asset Turnover is estimated to increase to 0.64, while Total Assets are projected to decrease to under 238.3 M.
Last ReportedProjected for 2024
Price Book Value Ratio(0.73)(0.69)
Enterprise Value Multiple(1.73)(1.81)
Price Fair Value(0.73)(0.69)
The analysis of Karyopharm Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Karyopharm Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Karyopharm Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.003

Technical Drivers

As of the 29th of March, Karyopharm Therapeutics secures the Downside Deviation of 6.27, risk adjusted performance of 0.0936, and Mean Deviation of 6.16. Karyopharm Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Karyopharm Therapeutics, which can be compared to its peers in the industry. Please verify Karyopharm Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Karyopharm Therapeutics is priced some-what accurately, providing market reflects its recent price of 1.51 per share. Please also check out Karyopharm Therapeutics total risk alpha, which is currently at (0.61) to check the company can sustain itself at a future point.

Karyopharm Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Karyopharm Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Karyopharm Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Karyopharm Therapeutics Predictive Daily Indicators

Karyopharm Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Karyopharm Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Karyopharm Therapeutics Forecast Models

Karyopharm Therapeutics' time-series forecasting models are one of many Karyopharm Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Karyopharm Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Karyopharm Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Karyopharm Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Karyopharm shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Karyopharm Therapeutics. By using and applying Karyopharm Stock analysis, traders can create a robust methodology for identifying Karyopharm entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin(0.98)(1.03)
Operating Profit Margin(0.89)(0.93)
Net Loss(0.98)(1.03)
Gross Profit Margin 0.96  0.78 

Current Karyopharm Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Karyopharm analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Karyopharm analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
6.67Strong Buy7Odds
Karyopharm Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Karyopharm analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Karyopharm stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Karyopharm Therapeutics, talking to its executives and customers, or listening to Karyopharm conference calls.
Karyopharm Analyst Advice Details

Karyopharm Stock Analysis Indicators

Karyopharm Therapeutics stock analysis indicators help investors evaluate how Karyopharm Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Karyopharm Therapeutics shares will generate the highest return on investment. By understating and applying Karyopharm Therapeutics stock analysis, traders can identify Karyopharm Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow136.3 M
Long Term Debt170.9 M
Common Stock Shares Outstanding114.2 M
Total Stockholder Equity-136.2 M
Tax Provision266 K
Property Plant And Equipment Net4.9 M
Cash And Short Term Investments192.1 M
Cash52.9 M
Accounts Payable3.1 M
Net Debt124.1 M
50 Day M A1.2467
Total Current Liabilities69.5 M
Other Operating Expenses275.6 M
Non Current Assets Total6.5 M
Non Currrent Assets Other1.3 M
Stock Based Compensation21.7 M
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.25)
Revenue Per Share
1.279
Quarterly Revenue Growth
0.005
Return On Assets
(0.27)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.